As a result, Merck increased and narrowed its guidance for annual revenue from a range of $46.4 to $47.4 billion to $47.4 to $47.9 billion, which represents a sales growth of 14% to 15%. Merck's portfolio had much to do with the performance of cancer powerhouse Keytruda, which raked in sales of $4.5 billion, a 22% increase from last year's third quarter. RELATED: Merck marks a first with global health org to license its COVID-19 pill Meanwhile, Gardasil blew away estimates by ringing up $2 billion in sales, a 68% increase from last year.